Press release
Primary Sclerosing Cholangitis Key Players : Acorda Therapeutics Inc, Conatus Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Gilead Sciences Inc, NGM Biopharmaceuticals Inc, Noxopharm Ltd, and Sirnaomics Inc Market Analysis and Forecast 2018-2022
Primary Sclerosing cholangitis (PSC)
Primary Sclerosing cholangitis (PSC)
Overview
Primary Sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.
Bile ducts are refer to as tubes which carry bile into the upper part of the bowel. The bile also enables the body to absorb vitamins A, D, E and K from our diet.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811462-primary-sclerosing-cholangitis-pipeline-review-h1-2018
Primary Sclerosing Cholangitis Industry Major Highlights:
Primary Sclerosing Cholangitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The report further guide in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Primary Sclerosing Cholangitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Apart from this various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Major Outlook for Primary Sclerosing Cholangitis Report:
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Sclerosing Cholangitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis
The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis.
- The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
Competitive Analysis for Primary Sclerosing Cholangitis
Key players are making innovative developments in Primary Sclerosing Cholangitis industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector.
The key players in this market are Albireo Pharma Inc, Arena Pharmaceuticals Inc, Cadila Healthcare Ltd, Dr. Falk Pharma GmbH, Gilead Sciences Inc, Novartis AG, Tiziana Life Sciences Plc and Virobay Inc
….. Continued
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Primary Sclerosing Cholangitis - Overview 6
Primary Sclerosing Cholangitis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 10
Primary Sclerosing Cholangitis - Therapeutics Assessment 11
Assessment by Target 11
Assessment by Mechanism of Action 13
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development 19
ActiveSite Pharmaceuticals Inc 19
Coherus BioSciences Inc 19
Lupin Ltd 20
Mabion SA 20
....
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2811462-primary-sclerosing-cholangitis-pipeline-review-h1-2018
Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.
WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Sclerosing Cholangitis Key Players : Acorda Therapeutics Inc, Conatus Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Gilead Sciences Inc, NGM Biopharmaceuticals Inc, Noxopharm Ltd, and Sirnaomics Inc Market Analysis and Forecast 2018-2022 here
News-ID: 932749 • Views: …
More Releases from WISE GUY RESEARCH CONSULTANTS PVT. LTD.
CBD Snack Market 2020- Global Industry Analysis, By Key Players, Segmentation, T …
Summary:
A new market study, titled “Discover Global CBD Snack Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.
Introduction
“CBD Snack Market”
COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and…
Chronic Lymphocytic Leukemia Global Key Players 4SC AG, AbbVie Inc, Baliopharm A …
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2017”
Chronic lymphocytic leukemia (CLL)
Overview
Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections…
Onychomycosis (Tinea Unguium) Global Key Players Almirall SA, Blueberry Therapeu …
WiseGuyReports.com with their unique quality of simplifying the market research study presents a deep diving study report “Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2018”
Onychomycosis (Tinea Unguium)
Overview
Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and…
Non Alcoholic Fatty Liver Disease Global Key Players Akcea Therapeutics Inc, Bet …
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2018”
Non Alcoholic Fatty Liver Disease (NAFLD)
Overview
Non Alcoholic Fatty Liver Disease (NAFLD) this situation arise when individual have too much fats there your liver. There should be little or no fat in a healthy liver and for most people, carrying a small amount of…
More Releases for Primary
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
